Antengene Corporation Limited will present new data from two clinical trials of selinexor at the 2024 American Society of Hematology (ASH) Annual Meeting, taking place December 7-10 in San Diego, CA. The presentations will feature results from a Phase III study in relapsed/refractory multiple myeloma (RRMM) and a Phase I/II study in relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL).
Selinexor, Bortezomib, and Dexamethasone (SVd) in Relapsed/Refractory Multiple Myeloma
The Phase III Bench study evaluated weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice-weekly bortezomib and dexamethasone (Vd) in Chinese patients with RRMM. This primary analysis offers insights into the efficacy and safety of the SVd regimen in this patient population. The details of the poster presentation are as follows:
- Title: Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase III Bench Study
- Publication Number: 4748
- Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III
- Date: Monday, December 9, 2024
- First Author: Dr. Jin Lu (Peking University People's Hospital)
- Corresponding Author: Dr. Jian Hou (Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine)
Selinexor and Tislelizumab in Relapsed/Refractory Extranodal NK/T-Cell Lymphoma
Antengene will also present preliminary results from Arm C of the TOUCH study, a multicenter, single-arm, Phase I/II trial, which investigates selinexor in combination with tislelizumab in patients with R/R ENKTL. This study arm explores the potential of combining selinexor with an anti-PD-1 antibody in this challenging lymphoma subtype. Details for this poster are:
- Title: Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch
- Publication Number: 4448
- Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III
- Date: Monday, December 9, 2024
- First Author: Dr. Rong Tao (Fudan University Shanghai Cancer Center)
- Corresponding Author: Dr. Huiqiang Huang (Sun Yat-Sen University Cancer Center)
About Selinexor
Selinexor (XPOVIO®) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. By blocking XPO1, selinexor promotes the accumulation of tumor suppressor proteins within the nucleus, leading to cell cycle arrest and apoptosis. It has demonstrated synergistic effects in combination regimens and offers a novel approach to cancer treatment. Antengene is currently evaluating selinexor in multiple clinical trials across various hematologic malignancies and solid tumors.
Antengene is dedicated to developing innovative therapies to address unmet medical needs in oncology, striving to "Treat Patients Beyond Borders."
